Valsartan for pulmonary hypertension: protection study
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether a blood pressure medicine called valsartan can help protect the lungs and heart in people with a specific type of pulmonary hypertension (Group 1 PAH). If you have PAH and are stable enough to walk 50 meters, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have Group 1 Pulmonary Arterial Hypertension (a specific type of high blood pressure in the lungs).
- You are in New York Heart Association class II, III, or IV (meaning you have some symptoms but can still walk).
- You have had a right heart catheterization in the last 5 years that showed certain pressures in your heart and lungs.
- You can walk at least 50 meters, with or without a walking aid.
- You have not taken ACE inhibitors, ARBs (like valsartan), or ARNIs in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
This trial tests a new oral medication, called CS1, that is added to your current PAH medications. The goal is to see if it helps improve your symptoms and ability to exercise.
This study looks at how your heart and lungs respond to starting a blood vessel–widening medication (a vasodilator) for pulmonary hypertension. It will closely monitor your breathing and heart rhythm to help doctors understand and improve treatment.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.